Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes
- PMID: 35533036
- DOI: 10.36849/JDD.6609
Insights in Skin of Color Patients With Atopic Dermatitis and the Role of Skincare in Improving Outcomes
Abstract
Background: Research on the role of race and ethnicity in the pathophysiology of atopic dermatitis (AD) is limited. Variations in the epidemiology, clinical presentation, and disease course in skin of color SOC AD patients have been reported. This manuscript seeks to offer insights into distinct features of AD in populations with (SOC) and provide recommendations on the role of skincare in treating AD amongst diverse populations.
Methods: A literature review followed by panel discussions and an online review process explored best clinical practices in treating AD patients with SOC and providing expert guidance for skincare use, including gentle cleansers and moisturizers.
Results: Some studies have identified differences in skin barrier properties in racial/ethnic groups affected by AD that may have implications for barrier function. Variations in the clinical presentation – including morphology, severity, and distribution – of AD in populations with SOC have been reported. Epidemiologic studies suggest a higher prevalence among self-identified Blacks/African Americans and greater health care utilization for AD among both Blacks/African Americans and Asian/Pacific Islanders. Pigmentary sequelae, including hyper- hypo- and depigmentation is a distinct feature of AD in patients with SOC that may contribute to the quality of life impact of the disorder. Xerosis may be more stigmatizing in SOC due to greater visibility of scale and dryness in the context of melanin-rich skin. Racial/ethnic variations in the prevalence of pruritus have also been reported, which may in turn have implications for AD in SOC. Treatment and maintenance of AD in patients with SOC should be proactive, effectively control inflammation longitudinally, include effective skin barrier protective strategies, and consider cultural practices.
Conclusion: Robust comparative studies are needed to better understand racial/ethnic variations in AD. Further research will help to tailor patient education and foster individualized approaches to treatment, prevention, and adjunctive skin care across the diverse spectrum of patient populations. J Drugs Dermatol. 2022;21(5):462-470. doi:10.36849/JDD.6609.
Similar articles
-
INDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color.J Drugs Dermatol. 2023 Aug 1;22(8):SF386361s3-SF386361s10. J Drugs Dermatol. 2023. PMID: 37556528
-
INDIVIDUAL ARTICLE: Atopic Dermatitis Skincare and Impact on Quality of Life for Patients with Skin of Color.J Drugs Dermatol. 2024 Mar 1;23(3):SF395747s6-SF395747s11. doi: 10.36849/jdd.SF395747. J Drugs Dermatol. 2024. PMID: 38443136 Review.
-
Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care.J Drugs Dermatol. 2022 Oct 1;21(10):1054-1060. doi: 10.36849/JDD.7090. J Drugs Dermatol. 2022. PMID: 36219055
-
Racial/Ethnic Variations in Acne: Implications for Treatment and Skin Care Recommendations for Acne Patients With Skin of Color.J Drugs Dermatol. 2021 Jul 1;20(7):716-725. doi: 10.36849/JDD.6169. J Drugs Dermatol. 2021. PMID: 34232006
-
Racial/Ethnic Variations in Skin Barrier: Implications for Skin Care Recommendations in Skin of Color.J Drugs Dermatol. 2021 Sep 1;20(9):932-938. doi: 10.36849/jdd.6312. J Drugs Dermatol. 2021. PMID: 34491028 Review.
Cited by
-
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study.Am J Clin Dermatol. 2025 Jul 15. doi: 10.1007/s40257-025-00970-8. Online ahead of print. Am J Clin Dermatol. 2025. PMID: 40665146
-
Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials.Dermatol Ther (Heidelb). 2025 Sep;15(9):2667-2682. doi: 10.1007/s13555-025-01489-w. Epub 2025 Jul 22. Dermatol Ther (Heidelb). 2025. PMID: 40696240 Free PMC article.
-
Presentations of Cutaneous Disease in Various Skin Pigmentations: Chronic Atopic Dermatitis.HCA Healthc J Med. 2024 Apr 30;5(2):103-111. doi: 10.36518/2689-0216.1644. eCollection 2024. HCA Healthc J Med. 2024. PMID: 38984232 Free PMC article.
-
Breast Cancer-Related Lymphedema Results in Impaired Epidermal Differentiation and Tight Junction Dysfunction.J Invest Dermatol. 2025 Jan;145(1):85-97.e4. doi: 10.1016/j.jid.2024.05.017. Epub 2024 Jun 13. J Invest Dermatol. 2025. PMID: 38879154
-
Dermatology in black skin.An Bras Dermatol. 2024 May-Jun;99(3):327-341. doi: 10.1016/j.abd.2023.10.001. Epub 2024 Feb 2. An Bras Dermatol. 2024. PMID: 38310012 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources